Vnitr Lek 2016, 62(12):998-1003

Oral antidiabetic drugs in treatment of type 1 diabetes mellitus

Ludmila Brunerová1,*, Jan Brož2
1 Diabetologické centrum II. interní kliniky 3. LF UK a FN Královské Vinohrady, Praha
2 Interní klinika 2. LF UK a FN v Motole, Praha

Review article summarizes current knowledge of the use of oral antidiabetics (approved for treatment of type 2 diabetes) in type 1 diabetic patients. Following drugs were tested: metformin, gliptines, analogues of GLP-1, glitazones, inhibitors of α-glukozidase and gliflozines. The latter seem to be the most perspective ones, however, more studies are warranted for definitive confirmation of their efficacy and safety. Current evidence-based results did not clearly show efficacy and safety of oral antidiabetics as adjuvant treatment in type 1 diabetic patients and thus, they still represent off-label treatment in this type of diabetes.

Keywords: oral antidiabetics; type 1 diabetes mellitus

Received: May 23, 2016; Accepted: September 27, 2016; Published: December 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Brunerová L, Brož J. Oral antidiabetic drugs in treatment of type 1 diabetes mellitus. Vnitr Lek. 2016;62(12):998-1003.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Proks P, Reimann F, Green N et al. Sulfonylurea Stimulation of Insulin Secretion. Diabetes 2002; 51(suppl 3): S368-S376. Go to original source... Go to PubMed...
    2. Rena G, Pearson ER, Sakamoto K. Molecular mechanism of action of metformin: old or new insights? Diabetologia 2013; 56(9): 1898-1906. Go to original source... Go to PubMed...
    3. Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev 2002; 18(Suppl 2): S10-S15. Go to original source... Go to PubMed...
    4. Haluzík M. Praktická léčba diabetu. 2. ed. Mladá fronta: Praha 2013. ISBN 978-80-204-2880-6.
    5. Bailey CJ, Day C. SGLT2 Inhibitors: Glucuretic Treatment for Type 2 Diabetes. Br J of Diabetes Vasc Dis 2010; 10(4): 193-199. Dostupné z DOI: <http://dx.doi.org/10.1177/1474651410377832>. Go to original source...
    6. Rodbard D. Continuous Glucose Monitoring: A Review of Successes, Challenges, and Opportunities. Diabetes Technol Ther 2016; 18(Suppl 2): S23-S213. Dostupné z DOI: <http://dx.doi.org/10.1089/dia.2015.0417>. Go to original source... Go to PubMed...
    7. Heinemann L, Benesch C, DeVries JH. [AP@home Consortium]. The Artificial Pancreas Is Now at Home. J Diabetes Sci Technol 2016; 10(4):950-958. Dostupné z DOI: <http://dx.doi.org/10.1177/1932296816632002. Go to original source... Go to PubMed...
    8. Nathan DM. Diabetes: Advances in Diagnosis and Treatment. JAMA 2015; 314(10): 1052-1062. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2015.9536>. Go to original source... Go to PubMed...
    9. Greeley SA, Naylor RN, Philipson LH et al. Neonatal diabetes: an expanding list of genes allows for improved diagnosis and treatment. Curr Diab Rep 201; 11(6): 519-532. Dostupné z DOI: <http://dx.doi.org/10.1007/s11892-011-0234-7. Go to PubMed...
    10. Anik A, Çatli G, Abaci A et al. Maturity-onset diabetes of the young (MODY): an update. J Pediatr Endocrinol Metab 2015; 28(3-4): 251-263. Dostupné z DOI: <http://dx.doi.org/10.1515/jpem-2014-0384>. Go to original source... Go to PubMed...
    11. Cleland SJ, Fisher BM, Colhoun HM et al. Insulin resistance in type 1 diabetes: what is 'double diabetes' and what are the risks? Diabetologia 2013; 56(7): 1462-1470. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125-013-2904-2>. Go to original source... Go to PubMed...
    12. Polsky S, Ellis SL. Obesity, insulin resistance, and type 1 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2015; 22(4): 277-282. Dostupné z DOI: <http://dx.doi.org/10.1097/MED.0000000000000170>. Go to original source... Go to PubMed...
    13. Munir KM, Davis SN. The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus. Expert Opin Pharmacother 2015; 16(15): 2331-2341. Dostupné z DOI: <http://dx.doi.org/10.1517/14656566.2015.1084502>. Go to original source... Go to PubMed...
    14. Viollet B, Guigas B, Sanz Garcia N et al. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012; 122(6): 253-270. Dostupné z DOI: <http://dx.doi.org/10.1042/CS20110386>. Go to original source... Go to PubMed...
    15. Libman IM, Miller KM, DiMeglio LA. T1D Exchange Clinic Network Metformin RCT Study Group. Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial. JAMA 2015; 314(21): 2241-2250. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2015.16174>. Go to original source... Go to PubMed...
    16. Konrad K, Datz N, Engelsberger I et al. [German/Austrian DPV Initiative]. Current use of metformin in addition to insulin in pediatric patients with type 1 diabetes mellitus: an analysis based on a large diabetes registry in Germany and Austria. Pediatr Diabetes 2015; 16(7): 529-537. Dostupné z DOI: <http://dx.doi.org/10.1111/pedi.12203>. Go to original source... Go to PubMed...
    17. Liu C, Wu D, Zheng X et al. Efficacy and safety of metformin for patients with type 1 diabetes mellitus: a meta-analysis. Diabetes Technol Ther 2015; 17(2): 142-148. Dostupné z DOI: <http://dx.doi.org/10.1089/dia.2014.0190>. Go to original source... Go to PubMed...
    18. Dupre J. Glycaemic effects of incretins in type 1 diabetes mellitus: A concise review, with emphasis on studies in humans. Regul Pept 2005; 128(2): 149-157. Erratum in Regul Pept 2006; 134(1): 67-68. Go to original source... Go to PubMed...
    19. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132(6): 2131-2157. Go to original source... Go to PubMed...
    20. Ellis SL, Moser EG, Snell-Bergeon JK et al. Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabet Med 2011; 28(10): 1176-1181. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1464-5491.2011.03331.x>. Go to original source... Go to PubMed...
    21. Kutoh E. Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series. J Med Case Rep 2011; 5: 117. Dostupné z DOI: http://dx.doi.org/<10.1186/1752-1947-5-117>. Go to original source... Go to PubMed...
    22. George PS, McCrimmon RJ. Saxagliptin co-therapy in C-peptide-negative Type 1 diabetes does not improve counter-regulatory responses to hypoglycaemia. Diabet Med 2016; 33(9): 1283-1290. Dostupné z DOI: <http://dx.doi.org/10.1111/dme.13046>. Go to original source... Go to PubMed...
    23. Farngren J, Persson M, Schweizer A et al. Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes. J Clin Endocrinol Metab 2012; 97(10): 3799-3806. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2012-2332>. Go to original source... Go to PubMed...
    24. Schopman JE, Hoekstra JB, Frier BM et al. Effects of sitagliptin on counter-regulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes: a randomized double-blind placebo-controlled crossover study. Diabetes Obes Metab 2015; 17(6): 546-553. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12453>. Go to original source... Go to PubMed...
    25. Unger J. Rationale use of GLP-1 receptor agonists in patients with type 1 diabetes. Curr Diab Rep 2013; 13(5): 663-668. Dostupné z DOI: <http://dx.doi.org/10.1007/s11892-013-0404. Go to original source... Go to PubMed...
    26. Dejgaard TF, Frandsen CS, Hansen TS et al. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2016; 4(3): 221-232. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213-8587(15)00436-2>. Go to original source... Go to PubMed...
    27. Frandsen CS, Dejgaard TF, Holst JJ et al. Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study. Diabetes Care 2015; 38(12): 2250-2257. Dostupné z DOI: <http://dx.doi.org/10.2337/dc15-1037>. Go to original source... Go to PubMed...
    28. Raman VS, Mason KJ, Rodriguez LM et al. The role of adjunctive exenatide therapy in pediatric type 1 diabetes. Diabetes Care 2010; 33(6): 1294-1296. Dostupné z DOI: <http://dx.doi.org/10.2337/dc09-1959>. Go to original source... Go to PubMed...
    29. Traina AN, Lull ME, Hui AC et al. Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy. Can J Diabetes 2014; 38(4): 269-272. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jcjd.2013.10.006>. Go to original source... Go to PubMed...
    30. Sarkar G, Alattar M, Brown RJ et al. Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes. Diabetes Care 2014; 37(3): 666-670. Dostupné z DOI: <http://dx.doi.org/10.2337/dc13-1473>. Go to original source... Go to PubMed...
    31. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351(11): 1106-1118. Go to original source... Go to PubMed...
    32. Bhat R, Bhansali A, Bhadada S et al. Effect of pioglitazone therapy in lean type 1 diabetes mellitus. Diabetes Res Clin Pract 2007; 78(3): 349-354. Go to original source... Go to PubMed...
    33. Tafuri KS, Godil MA, Lane AH et al. Effect of pioglitazone on the course of new-onset type 1 diabetes mellitus. J Clin Res Pediatr Endocrinol 2013; 5(4): 236-239. Dostupné z DOI: <http://dx.doi.org/10.4274/Jcrpe.981>. Go to original source... Go to PubMed...
    34. Yang Z, Zhou Z, Li X et al. Rosiglitazone preserves islet beta-cell function of adult-onset latent autoimmune diabetes in 3 years follow-up study. Diabetes Res Clin Pract 2009; 83(1): 54-60. Dostupné z DOI: <http://dx.doi.org/10.1016/j.diabres.2008.09.044>. Go to original source... Go to PubMed...
    35. Stone ML, Walker JL, Chisholm D et al. The addition of rosiglitazone to insulin in adolescents with type 1 diabetes and poor glycaemic control: a randomized-controlled trial. Pediatr Diabetes 2008; 9(4 Pt 1): 326-334. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1399-5448.2008.00383.x>. Go to original source... Go to PubMed...
    36. Kubo S, Watada H, Kawamori R. Combination therapy of miglitol and insulin in type 1 diabetes mellitus patients. J Diabetes Investig 2010; 1(1-2): 60-65. Dostupné z DOI: <http://dx.doi.org/10.1111/j.2040-1124.2010.00011.x>. Go to original source... Go to PubMed...
    37. Nagai E, Katsuno T, Miyagawa J et al. Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special reference to incretin responses in type 1 diabetes mellitus. Endocr J 2011; 58(10): 869-877. Go to original source... Go to PubMed...
    38. Riccardi G, Giacco R, Parillo M et al. Efficacy and safety of acarbose in the treatment of Type 1 diabetes mellitus: a placebo-controlled, double-blind, multicentre study. Diabet Med 1999; 16(3): 228-232. Go to original source... Go to PubMed...
    39. Rabasa-Lhoret R, Burelle Y, Ducros F et al. Use of an alpha-glucosidase inhibitor to maintain glucose homoeostasis during postprandial exercise in intensively treated Type 1 diabetic subjects. Diabet Med 2001; 18(9): 739-744. Go to original source... Go to PubMed...
    40. Henry RR, Thakkar P, Tong C et al. Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes. Diabetes Care 2015; 38(12): 2258-2265. Dostupné z DOI: <http://dx.doi.org/10.2337/dc15-1730>. Go to original source... Go to PubMed...
    41. Henry RR, Rosenstock J, Edelman S et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care 2015; 38(3): 412-419. Dostupné z DOI: <http://dx.doi.org/10.2337/dc13-2955>. Go to original source... Go to PubMed...
    42. Pieber TR, Famulla S, Eilbracht J et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab 2015; 17(10): 928-935. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12494>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.